Cepheid

At the recent CVS, the two large health systems described introducing Cepheid platforms for flu testing across rural and satellite locations.

FIND is granting an award to Altona Dx, Cepheid, and the Bernhard Nocht Institute to develop an assay for Lassa virus. It also signed an MOU with the UK government to combat antimicrobial resistance.

The test for resistance genes from carbapenemase-producing Gram-negative bacteria can now be used on perirectal swabs and pure colonies.

The test, which received FDA clearance in late 2017, runs in as little as 18 minutes.

The company's Diagnostics business was up 14 percent, while its Life Sciences business grew 13 percent. The firm also closed its $2 billion buy of IDT last week.

The agency cleared two Roche tests that run on its Cobas systems. One does Chlamydia trachomatis and Neisseria gonorrhoeae testing and the other does hematology testing.

Alere received FDA 510(k) clearances for four tests, including those for influenza A and B, strep A, and RNA-based respiratory syncytial virus.

In Life Sciences, CEO Thomas Joyce noted a strong performance by Beckman Coulter, while in Diagnostics, he said Cepheid grew 25 percent year over year. 

The new instrument has higher throughput than competing systems, while the flu test boasts enhanced sensitivity and protection against seasonal drift.

The Xpert Xpress Flu can detect both influenza A and B virus in 20 minutes from either nasopharyngeal or nasal swabs.

Pages